News > Latest News

Walk News | Sponsor & Foundation News | News in the Parkinson's Disease Community

Voyager Therapeutics Highlights Lead Program VY-AADC for Advanced PD

(November 17, 2017) - Voyager Therapeutics, Inc., a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, highlighted recent progress and plans for VY-AADC for advanced Parkinson’s disease at its recent R&D Day. Plans to begin the global, pivotal Phase 2-3 program for VY-AADC before year-end 2017 and dose the first patient during the second quarter of 2018. Voyager remains on track to file an investigational new drug (IND) application before year-end 2017 with product for VY-AADC manufactured using its baculovirus/Sf9 manufacturing process to support this pivotal program.  Read more